Artonin E mediates MCL1 down-regulation and sensitizes lung cancer cells to anoikis

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5343-5351

  Wongpankam, Ekkarat ^a   Chunhacha, Preedakorn ^a,b   Pongrakhananon, Varisa ^a,b   Sritularak, Boonchoo ^b   Chanvorachote, Pithi ^a,b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

A549; Anoikis; Artonin E; H292; H460; Hk2 cells; Lung cancer cells; MCL1; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; ARTONIN E; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

ANOIKIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; FLAVONOIDS; HUMANS; KIDNEY; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84872526562     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW and Heo DS: Prognostic factors for non-small cell lugn cancer with bone metastasis at the time of diagnosis. Lung cancer 77(3): 572-577, 2012.
2. Cheran SK, Herndon JE 2nd and Patz EF Jr.: Comparison of whole-body FDG PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 44: 317-325, 2004.
3. Zhong X and Rescorla FJ: Cell surface adhesion molecules and adhesion-initiated signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cell Signal 24: 393-401, 2012.
4. Chiarugi P and Giannoni E: Anoikis: A necessary death program for anchorage-dependent cells. Biochem Pharmacol 76: 1352-1364, 2008.
5. Gilmore AP: Anoikis. Cell Death Differ 12: 1473-1477, 2005.
6. Kim YN, Koo KH, Sung JY, Yun UJ and Kim H: Anoikis resistance: An essential prerequisite for tumor metastasis. Int J Cell Biol 2012: 2012.
7. Simpson CD, Anyiwe K and Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett 272: 177-185, 2008.
8. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, Aitken A, Khuri FR and Fu H: Down-regulation of 14-3-3zeta suppresses anchorage independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 105: 162-167, 2008.
9. Kodama K, Ishii G, Miyamoto S, Goya M, Zhang SC, Sangai T, Yoshikawa T, Hasebe T, Hitomi Y, Izumi K and Ochiai A: Laminin 5 expression protects against anoikis at aerogenous spread and lepidic growth of human lung adenocarcinoma. Int J Cancer 116: 876-884, 2005.
10. Wei L, Yang Y, Zhang X and Yu Q: Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 23: 9052-9061, 2004.
11. Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124: 619-626, 1994.
12. Rosen K, Rak J, Leung T, Dean NM, Kerbel RS and Filmus J: Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. J Cell Biol 149: 447-456, 2000.
13. Rosen K, Rak J, Jin J, Kerbel RS, Newman MJ and Filmus J: Down-regulation of the proapoptotic protein Bak is required for the Ras-induced transformation of Intestinal epithelial cells. Curr Biol 8: 1331-1334, 1998.
14. Coll ML, Rosen K, Ladeda V and Filmus J: Increased Bcl-xL expression mediates v-Src induced resistance to anoikis in intestinal epithelial cells. Oncogene 21: 2908-2913, 2002.
15. Galante JM, Mortenson MM, Bowles TL, Virudachalam S and Bold RJ: ERK/BCL2 pathway in the resistance of pancreatic cancer to anoikis. J Surg Res 152: 18-25, 2009.
16. Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y and Chanvorachote P: Curcumin sensitizes non-small cell lung cancer cell anoikis through reactive oxygen species-mediated BCL2 down-regulation. Apoptosis 15: 574-585, 2010.
17. Bondar VM and McConkey DJ: Anoikis is regulated by BCL2-independent pathways in human prostate carcinoma cells. Prostate 51: 42-49, 2002.
18. Boisvert-Adamo K, Longmate W, Abel EV and Aplin AE: MCL1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7: 549-556, 2009.
19. Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95: 4997-5002, 1998.
20. Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 2: 271-278, 2000.
21. Valentijn AJ, Metcalfe AD, Kott J, Streuli CH and Gilmore AP: Spatial and temporal changes in Bax subcellular localization during anoikis. J Cell Biol 162: 599-612, 2003.
22. Valentijn AJ and Gilmore AP: Translocation of full-length Bid to mitochondria during anoikis. J Biol Chem 279: 32848-32857, 2004.
23. Owens TW, Valentijn AJ, Upton JP, Keeble J, Zhang L, Lindsay J, Zouq NK and Gilmore AP: Apoptosis commitment and activation of mitochondrial BAX during anoikis is regulated by p38MAPK. Cell Death Differ 16: 1551-1562, 2009.
24. Jagtap UB and Bapat VA: Artocarpus: A review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol 129: 142-166, 2010.
25. Barron D and Ibrahim RK: Isoprenylated flavonoids a survey. Phytochemistry 43: 921-982, 1996.
26. Suhartati T, Yandri and Hadi S: The Bioactivity Test of Artonin E from the Bark of Artocarpus rigida Blume. Eur J Sci Res 23: 330-337, 2008.
27. Boonphong S, Baramee A, Kittakoop P and Puangsombat P: Antitubercular and antiplasmodial prenylated flavones from the roots of Artocarpus altilis. Chiang Mai J Sci 34: 339-344, 2007.
28. Woods NT, Yamaguchi H, Lee FY, Bhalla KN and Wang HG: Anoikis, initiated by MCL1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 67: 10744-10752, 2007.
29. Chunhacha P, Pongrakhananon V, Rojanasakul Y and Chanvorachote P: Caveolin-1 regulates MCL1 stability and anoikis in lung carcinoma cells. Am J Physiol Cell Physiol 302: 1284-1292, 2012.
30. Fiucci G, Ravid D, Reich R and Liscovitch M: Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21: 2365-2375, 2002.
31. Rungtabnapa P, Nimmannit U, Halim H, Rojanasakul Y and Chanvorachote P: Hydrogen peroxide inhibits non-small cell lung cancer cell anoikis through the inhibition of caveolin-1 degradation. Am J Physiol Cell Physiol 300: 235-245, 2011.
32. Chanvorachote P, Nimmannit U, Lu Y, Talbott S, Jiang BH and Rojanasakul Y: Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem 284: 28476-28484, 2009.
33. Martini N, Flehinger BJ, Zaman MB and Beattie EJ Jr.: Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 198: 386-397, 1983.
34. Wakelee H and Belani CP: Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 10: 1-10, 2005.
35. Gompelmann D, Eberhardt R and Herth FJ: Advanced malignant lung disease: What the specialist can offer. Respiration 82: 111-123, 2011.
36. Kataoka M, Schumacher G, Cristiano RJ, Atkinson EN, Roth JA and Mukhopadhyay T: An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo. Cancer Res 58: 4761-4765, 1998.
37. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M and Fujisawa T: A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917, 2005.
38. Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J and Gridelli C: Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 45: 2473-2487, 2009.
39. Silvestri GA and Rivera MP: Targeted therapy for the treatment of advanced non-small cell lung cancer: A review of the epidermal growth factor receptor antagonists. Chest 128: 3975-3984, 2005.
40. Indovina P, Marcelli E, Pentimalli F, Tanganelli P, Tarro G and Giordano A: Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery. Mass Spectrom Rev. 2012.
41. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC and Glinsky GV: Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65: 2378-2386, 2005.
42. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E and Peeper DS: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034-1039, 2004.
43. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK and Chung DH: Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 42: 195-202, 2003.
44. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH and Yang PC: Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 59: 105-110, 2008.
45. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is sequestered by MCL1 and Bcl-xL, but not BCL2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005.
46. Clohessy JG, Zhuang J, de Boer J, Gil-Gómez G and Brady HJ: MCL1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 281: 5750-5759, 2006.
47. Gores GJ and Kaufmann SH: Selectively targeting MCL1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev 26: 305-311, 2012.
48. Akgul C: MCL1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326-1336, 2009.
49. Warr MR and Shore GC: Unique biology of MCL1: Therapeutic opportunities in cancer. Curr Mol Med 8: 138-147, 2008.